{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000008","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.364029+00:00","generated_at":"2026-05-27T22:13:48.880876+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Keros-Takeda license for elritercept effective; $200M upfront payment triggered","bullets":["Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.","Upfront payment of $200.0 million from Takeda to Keros was triggered upon effectiveness.","Agreement was previously announced on Dec 3, 2024; effectiveness followed HSR waiting period expiration.","Elritercept is a clinical-stage therapy targeting TGF-ß family signaling disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000008","json":"https://secwatch.observer/filing/0001664710-25-000008.json","markdown":"https://secwatch.observer/filing/0001664710-25-000008.md","text":"https://secwatch.observer/filing/0001664710-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/0001664710-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/kros-20250116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:13:48.880876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}